Drugs / Botulinum toxin
Botulinum toxin
also known as
Botox · Botulinum neurotoxin · BoNT · BTX · BTX-A · Botulinum toxin A · Dysport · BoNTA · +6 more
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed detrusor sphincter dyssynergia 1 milestone | |||||
| Filed | US (FDA) | BOTOX | detrusor sphincter dyssynergia | 2020-06-22 | “FDA has accepted the company's supplemental biologics license application (sBLA) to expand the BOTOX ® prescribing information” abbvie.com ↗ |
| Filed masticatory muscles, hypertrophy of 1 milestone | |||||
| Filed | US (FDA) | BOTOX Cosmetic | masticatory muscles, hypertrophy of | 2026-08-04 | “FDA has accepted for review its supplemental Biologics License Application (sBLA) for BOTOX® Cosmetic” abbvie.com ↗ |
| Rejected Indication not stated 2 milestones | |||||
| Rejected (CRL) | US (FDA) | — | glabellar lines | 2026-04-23 | “received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for trenibotulinumtoxinE” abbvie.com ↗ |
| Rejected (CRL) | US (FDA) | — | glabellar and lateral canthal lines | 2023-10-03 | “Galderma has confirmed receipt from the FDA of a Complete Response Letter related to its Biologics License Application for liquid botulinum toxin type A (QM-1114)” ipsen.com ↗ |
Trials 47
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05062902 | Sep 2025 → Aug 2027 expected | chronic pain syndrome, interstitial cystitis, pelvis syndrome | HillMed Inc. | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT04523506 | May 2020 → Apr 2021 | scleroderma | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 18 trials | ||||||
| Phase 1 | NCT06796985 | Feb 2025 → Mar 2027 expected | — | University of Miami | Recruiting | No outcome recorded |
| Phase 1 | NCT04630873 | Nov 2020 → Aug 2025 overdue | spastic hemiplegia | University of Ioannina | Recruiting | No outcome recorded |
| Phase 1 | NCT04030767 | Sep 2019 → Sep 2020 | gingival overgrowth | Cairo University | Unknown | No outcome recorded |
| Phase 1 | NCT02139319 | Mar → Jul 2014 | osteoarthritis, knee | Galderma R&D | Completed | No outcome recorded |
| Phase 1 | NCT02003027 | Jun 2013 → Dec 2015 | — | Meshalkin Research Institute of Pathology of Circulation | Unknown | No outcome recorded |
| Phase 1 | NCT02003001 | Jun 2013 → Mar 2016 | ventricular tachycardia | Meshalkin Research Institute of Pathology of Circulation | Unknown | No outcome recorded |
| Phase 1 | NCT01682733 | Aug 2012 → Dec 2014 | obesity disorder | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT00767546 | May 2009 → Aug 2010 | Parkinson disease, seborrheic dermatitis | Rabin Medical Center | Unknown | No outcome recorded |
| Phase 26 trials · 1 missed | ||||||
| Phase 2 | NCT04409600 | Nov 2020 → Dec 2024 | compartment syndrome | Walter Reed National Military Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT02982434 | Sep 2016 → Dec 2017 | atrial fibrillation, ischemic disease | Meshalkin Research Institute of Pathology of Circulation | Unknown | No outcome recorded |
| Phase 2 | NCT02623829 | Dec 2015 → Mar 2019 | keloid formation | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT02867787 | Mar 2014 → Sep 2016 | rotator cuff syndrome | Versailles Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01955174 | Aug 2013 → May 2017 | esophageal disorder | Hospices Civils de Lyon | Completed | Missed primary |
| Phase 2 | NCT00973999 | Sep 2009 → Sep 2011 | traumatic brain injury | HCA International Limited | Withdrawn | No outcome recorded |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT05478551 | Jun 2022 → Dec 2026 expected | reactive cutaneous fibrous lesion | Henry Ford Health System | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT03339921 | Dec 2018 → May 2020 | compartment syndrome | 375th Medical Group, Scott Air Force Base | Terminated | No outcome recorded |
| Phase 2/3 | NCT02617069 | Sep 2015 → Mar 2016 | atrial fibrillation | Meshalkin Research Institute of Pathology of Circulation | Unknown | No outcome recorded |
| Phase 2/3 | NCT01780636 | Jan 2013 → Jan 2014 | anismus | Karen Noblett | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT00133861 | Apr 2005 → Jun 2008 | cerebral palsy | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 37 trials · 1 met primary | ||||||
| Phase 3 | NCT05998187 | Apr 2025 → Jun 2027 expected | — | University Hospital, Rouen | Recruiting | No outcome recorded |
| Phase 3 | NCT05008731 | Jul 2024 → Feb 2026 | congenital contractures | Ramsay Santé | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT05990881 | Aug 2023 → Dec 2025 overdue | carpal displacement, salivary substance, Clostridium botulinum type, thumb deformity | Rhode Island Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT04249687 | Feb → Sep 2020 | eyelid disorder | Galderma R&D | Completed | Met primary |
| Phase 3 | NCT04579419 | Nov 2019 → Aug 2020 | — | King Abdulaziz Medical City | Completed | No outcome recorded |
| Phase 3 | NCT01829763 | Apr 2013 → Apr 2015 | hemiplegia | Assistance Publique Hopitaux De Marseille | Unknown | No outcome recorded |
| Phase 3 | NCT01422161 | Apr 2010 → Oct 2015 | stroke disorder | NYU Langone Health | Completed | No outcome recorded |
| Phase 47 trials | ||||||
| Phase 4 | NCT06411028 | Jan 2025 → May 2027 expected | dystonic disorder | Radboud University Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT06734598 | Dec 2024 → Nov 2025 overdue | head and neck cancer | National Taiwan University Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06080438 | Nov 2022 → Jul 2024 | excessive tearing, eyelid disorder | University of Miami | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04829565 | Sep 2021 → May 2025 overdue | arthropathy, erosive | Centre Hospitalier Universitaire de Nice | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03701919 | Jan 2019 → Nov 2022 | — | Albany Medical College | Completed | No outcome recorded |
| Phase 4 | NCT02786550 | Jun 2016 → Jun 2018 | eyelid degenerative disorder | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00119886 | Apr 2005 → Jun 2008 | vulvar disease, vulvodynia | Rigshospitalet, Denmark | Unknown | No outcome recorded |
| Phase not applicable12 trials · 1 met primary | ||||||
| — | NCT07180394 | Sep 2025 → Aug 2030 expected | strabismus | Foundation University Islamabad | Not yet recruiting | No outcome recorded |
| — | NCT07025642 | Jul 2025 → May 2026 overdue | overactive bladder | Mackay Medical College | Recruiting | No outcome recorded |
| — | NCT06733025 | Jan 2025 → Jan 2029 expected | spinal cord injury, stroke disorder, traumatic brain injury | Vastra Gotaland Region | Recruiting | No outcome recorded |
| — | NCT06593821 | Apr 2023 → Jan 2024 | bruxism, masticatory muscles, hypertrophy of | Zonguldak Bulent Ecevit University | Completed | Met primary |
| — | NCT07124806 | Jul → Nov 2022 | movement disorder, spastic hemiplegia, stroke disorder | Universidad de los Andes, Chile | Completed | No outcome recorded |
| — | NCT04177186 | Oct 2020 → Aug 2021 | cerebral palsy spastic hemiplegic, spastic diplegia | Asir John Samuel | Unknown | No outcome recorded |
| — | NCT03938363 | Oct 2019 → Jun 2022 | benign essential blepharospasm, cervical dystonia | University Hospital, Grenoble | Completed | No outcome recorded |
| — | NCT03836638 | May 2019 → Dec 2020 | salivary substance, Clostridium botulinum type | St Joseph University, Beirut, Lebanon | Unknown | No outcome recorded |
| — | NCT03247868 | Mar 2016 → Mar 2018 | cervical dystonia | Fondazione Don Carlo Gnocchi ETS | Unknown | No outcome recorded |
| — | NCT02244671 | Jan 2014 → Jan 2018 | eye adnexa disorder | Fox, Donald Munro, M.D., P.C. | Completed | No outcome recorded |
| — | NCT01631604 | Jun 2012 → Jun 2017 | movement disorder | Hadassah Medical Organization | Unknown | No outcome recorded |
| — | NCT03405948 | May 2006 → May 2009 | clubfoot | Assistance Publique Hopitaux De Marseille | Completed | No outcome recorded |
| Comparator or background therapy20 trials | ||||||
| Phase 1 | NCT04439825 Comparator | Jul → Sep 2020 | — | DeNova Research | Completed | No outcome recorded |
| Phase 1/2 | NCT02015039 Background | Dec 2013 → Sep 2016 | focal, segmental or multifocal dystonia | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 2 | NCT02008448 Comparator | Jun 2013 → Dec 2015 | persistent atrial fibrillation | Meshalkin Research Institute of Pathology of Circulation | Unknown | No outcome recorded |
| Phase 2 | NCT02008461 Comparator | Jun 2013 → Dec 2015 | cardiac rhythm disease | Meshalkin Research Institute of Pathology of Circulation | Unknown | No outcome recorded |
| Phase 2 | NCT02002923 Comparator | Jun 2013 → Jun 2015 | paroxysmal atrial fibrillation, persistent atrial fibrillation | Meshalkin Research Institute of Pathology of Circulation | Unknown | No outcome recorded |
| Phase 2 | NCT01842529 Comparator | Sep 2012 → Dec 2013 | paroxysmal atrial fibrillation | Meshalkin Research Institute of Pathology of Circulation | Completed | No outcome recorded |
| Phase 2 | NCT00701233 Comparator | Jun 2012 → Oct 2018 | carpal tunnel syndrome | University of Minnesota | Withdrawn | No outcome recorded |
| Phase 2 | NCT00015457 Background | Apr 2001 → Apr 2009 | focal dystonia | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 3 | NCT01586819 Comparator | Sep 2011 → May 2013 | — | Loyola University | Completed | No outcome recorded |
| Phase 4 | NCT05125029 Comparator | Feb 2022 → Dec 2025 overdue | Raynaud disease | Emory University | Recruiting | No outcome recorded |
| Phase 4 | NCT03302741 Background | Nov 2017 → Nov 2019 | — | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT02361749 Comparator | Sep 2014 → Aug 2018 | constipation disorder | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT02472210 Comparator | Jul 2014 → Jul 2015 | Parkinson disease | University Health Network, Toronto | Unknown | No outcome recorded |
| Phase 4 | NCT01032954 Comparator | Nov 2009 → Dec 2010 | — | Hexsel Dermatology Clinic | Completed | No outcome recorded |
| — | NCT07057050 Background | Jun → Oct 2025 | stroke disorder | Cairo University | Completed | No outcome recorded |
| — | NCT06583551 Comparator | Jan → Mar 2021 | bruxism | University of Health Sciences | Completed | No outcome recorded |
| — | NCT03546959 Background | Jun 2018 → Feb 2019 | stroke disorder | Marmara University | Completed | No outcome recorded |
| — | NCT02711995 Comparator | Dec 2015 → Sep 2016 | essential tremor | Weill Medical College of Cornell University | Completed | No outcome recorded |
| — | NCT00845897 Comparator | Mar 2005 → Mar 2010 | diabetes mellitus, peripheral neuropathy, ulcer of lower limbs | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT00927849 Comparator | Sep 2002 → Apr 2008 | rectal disorder | Mansoura University | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 89
| Date | Issuer | Release |
|---|---|---|
| 2026-09-17 | Merz Therapeutics GmbH | Regulatory Merz Therapeutics Receives EU/EEA Approval for XEOMIN ® for the Treatment of Pediatric Spasticity associated with Pes Equinus merztherapeutics.com ↗
Approval expands XEOMIN use to include the symptomatic treatment of spasticity associated with pes equinus in children and adolescents with cerebral palsy aged 2 to 17 years. |
| 2026-09-09 | AEON Biopharma, Inc. | Results AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX® aeonbiopharma.com ↗
Under thermal stress, both ABP-450 and BOTOX ® lost potency at comparable rates. |
| 2026-08-19 | AEON Biopharma, Inc. | Results AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX® aeonbiopharma.com ↗
The expanded primary structure analysis achieved 98% sequence coverage of the active botulinum neurotoxin and demonstrated 100% amino acid identity across every region analyzed. |
| 2026-08-04 | AbbVie | Regulatory Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence abbvie.com ↗ |
| 2026-07-09 | Ipsen | Results Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine. ipsen.com ↗
The E-BEOND results represent the first Phase III trial in which a botulinum toxin has demonstrated statistically significant efficacy in episodic migraine. |
| 2026-05-19 | Ipsen | Results Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity ipsen.com ↗
The DIRECTION trial results show the safety profile for Dysport® (abobotulinumtoxinA) was non-inferior to Botox® (onabotulinumtoxinA) in adult patients with upper limb spasticity |
| 2026-05-12 | Merz Therapeutics GmbH | Results Merz Therapeutics’ Activities at ISPRM 2026 Highlight the Importance of Patient-Centric Management in Upper and Lower Limb Spasticity: From Goal Setting to Optimal Dosing for Better Patient Outcomes merztherapeutics.com ↗
Updated analysis indicates that optimizing botulinum toxin dosing over multiple injection cycles may be an important factor in improving outcomes in people living with limb spasticity, with available clinical data suggesting support for flexible, individualized dosing with incobotulinumtoxinA (XEOMIN ® ) |
| 2026-04-13 | Cutia Therapeutics（Wuxi）Co.,Ltd | Results VOLUNTARY ANNOUNCEMENT - COMPLETION OF PHASE III CLINICAL TRIAL OF CU-20101 (BOTULINUM TOXIN TYPE A FOR INJECTION) FOR IMPROVING MODERATE TO SEVERE GLABELLAR LINES IN CHINA cutiatx.com ↗
COMPLETION OF PHASE III CLINICAL TRIAL OF CU-20101 (BOTULINUM TOXIN TYPE A FOR INJECTION) FOR IMPROVING MODERATE TO SEVERE GLABELLAR LINES IN CHINA |
| 2026-03-30 | AbbVie | Results Allergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 American Academy of Dermatology Meeting (AAD) abbvie.com ↗
TrenibotE is an investigational first-in-class botulinum neurotoxin serotype E characterized by rapid results, as early as 8 hours after administration (earliest assessment time), and shorter duration of effect of 2-3 weeks. |
| 2026-03-26 | AbbVie | Results Allergan Aesthetics Reinforces Scientific Differentiation and Leadership with 21 Evidence-Based E-Posters at the 2026 Aesthetic & Anti-Aging Medicine World Congress (AMWC) abbvie.com ↗ |
| 2026-01-26 | Merz Therapeutics GmbH | Regulatory Merz Therapeutics Submits Application for New Indication of XEOMIN ® in Pediatric Spasticity in Europe merztherapeutics.com ↗
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has completed the regulatory submission for XEOMIN® (incobotulinumtoxinA) for the treatment of spasticity of the lower and upper limb in children and adolescents aged 2–17 years in the European Union (EU) and European Economic Area (EEA). |
| 2026-01-22 | Galderma R&D | Results IMCAS 2026: Galderma showcases the latest scientific advances behind the industry’s broadest injectable aesthetics portfolio galderma.com ↗
New data on the innovative neuromodulator Relfydess™ (RelabotulinumtoxinA) will reinforce its rapid onset as early as Day 1 and sustained efficacy through six months for frown lines and crow’s feet12 |
| 2026-01-14 | Galderma R&D | Results TOXINS 2026: Clinical updates on Galderma’s leading neuromodulator portfolio further reinforce its leadership in Injectable Aesthetics galderma.com ↗
Dysport® (AbobotulinumtoxinA) data demonstrating high levels of patient and practitioner satisfaction after treatment of frown lines will also be presented |
| 2026-01-09 | Huons Biopharma | Regulatory Huons BioPharma Secures NMPA Approval for Type A Botu-linum Toxin in China huonsbiopharma.com ↗
Huons BioPharma Co., Ltd. (CEO: Yeong-Mok Kim) announced on the 9th that its Chinese partner, IMeik Technology, has received marketing authorization from the National Medical Products Administration (NMPA) of China for Hutox (domestic brand name: LIZTOX). |
| 2025-11-13 | AEON Biopharma, Inc. | Results AEON Biopharma Reports Positive and Robust Biosimilarity Results: Identical Amino Acid Sequence and Highly Similar Functional Analysis Data aeonbiopharma.com ↗
100% amino acid sequence identity confirmed between ABP-450 and BOTOX®, based on sequence coverage of 93% - 99% for the five proteins that comprise the 900kD botulinum toxin type A complex. |
| 2025-07-31 | Evolus, Inc. | Results Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins evolus.com ↗
Jeuveau ® and Dysport ® demonstrated significantly faster visible effects at Day 3 compared to Botox ® and Xeomin ® . |
| 2025-06-24 | Teijin America, Inc. | Regulatory Teijin Pharma Receives Approval for Additional Indication for XEOMIN® in Japan[Teijin Pharma] teijin.com ↗
XEOMIN® has become the first-ever drug approved for this indication in Japan. |
| 2025-06-24 | Merz Therapeutics GmbH | Regulatory Teijin Receives Approval for Additional Indication for XEOMIN® in Japan merztherapeutics.com ↗
Teijin Pharma Limited , the core company of Teijin Group ’s healthcare business, and Merz Therapeutics GmbH , a leader in the field of neurotoxins, jointly announced today that Teijin Pharma has received approval from Japan’s Ministry of Health, Labor and Welfare (MHLW) for an additional indication for XEOMIN ® (incobotulinumtoxinA) for the treatment of chronic sialorrhea. |
| 2025-04-25 | AbbVie | Regulatory AbbVie Reports First-Quarter 2025 Financial Results abbvie.com ↗
AbbVie announced that it submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of trenibotulinumtoxinE (BoNT/E) for the treatment of moderate to severe glabellar lines. |
| 2025-03-20 | Galderma R&D | Results AMWC 2025: Galderma pushes the innovation frontier with updates from its unparalleled portfolio designed to meet the needs of the aesthetic community galderma.com ↗
Galderma will present new data from across its portfolio, including findings from the RELAX and EXPRESSION studies on Relfydess® (RelabotulinumtoxinA) highlighting its rapid onset of action as early as day one and sustained high patient satisfaction beyond six months1,2 |
| 2025-01-31 | Galderma R&D | Results IMCAS 2025: New Galderma phase IIIb data reinforce rapid onset and long-lasting aesthetic improvement with RelabotulinumtoxinA (Relfydess™) galderma.com ↗
First results from the phase IIIb RELAX clinical trial reinforce the high and sustained efficacy of single treatment of RelabotulinumtoxinA (RelfydessTM) for moderate to severe frown lines (glabellar lines) beyond 6 months |
| 2025-01-23 | Galderma R&D | Results IMCAS 2025: Galderma’s broad presence and new data on recently launched products Restylane® SHAYPE™ and Relfydess® reaffirm its category leadership galderma.com ↗
including results from the phase IIIb RELAX trial, reinforcing its long-term efficacy and high patient satisfaction |
| 2024-12-20 | Merz Aesthetics Inc. | Results MERZ AESTHETICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 STUDY OF XEOMIN® (incobotulinumtoxinA) FOR TREATMENT OF PLATYSMA PROMINENCE merzaesthetics.com ↗
The study met its primary endpoint. |
| 2024-12-17 | Merz Therapeutics GmbH | Regulatory Health Canada Approves XEOMIN® (incobotulinumtoxinA) for Treatment of Adults with Post-stroke Lower Limb Spasticity in the Ankle and Foot merztherapeutics.com ↗
This approval means that adult patients who have suffered from a stroke and are experiencing lower limb spasticity in the ankle and foot will now have a safe and effective treatment option, |
| 2024-10-21 | Galderma R&D | Results ASDS 2024: new phase III READY-4 data demonstrate long-term safety and efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™) galderma.com ↗
First results from the phase III READY-4 trial demonstrate the long-term safety of repeated injections of RelabotulinumtoxinA for both frown lines and crow’s feet, with efficacy and patient satisfaction maintained across multiple treatments1 |
| 2024-10-18 | AbbVie | Regulatory BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands) abbvie.com ↗
Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of BOTOX ® Cosmetic for temporary improvement in the appearance of moderate to severe vertical bands connecting the jaw and neck (platysma bands) in adults. |
| 2024-07-30 | Galderma R&D | Regulatory Galderma’s Relfydess™ (RelabotulinumtoxinA) receives positive decision for use in Europe galderma.com ↗
Galderma today announced that it has completed its European decentralized procedure (DCP), resulting in a positive decision for RelfydessTM (RelabotulinumtoxinA – previously referred to as QM1114). |
| 2024-06-19 | Galderma R&D | Regulatory Galderma granted key manufacturing license updates for new biologics capabilities at its center of excellence galderma.com ↗
The license updates, issued following the agency’s good manufacturing practices (GMP) inspection of Galderma’s center of excellence in Uppsala, Sweden, enable Galderma to manufacture and perform bioanalytical testing on RelabotulinumtoxinA (QM1114). |
| 2024-04-17 | Evolus, Inc. | Results Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau® evolus.com ↗
Data showed duration effect of 26 weeks, or 6 months, based on a ≥ 1-point Glabellar Line Scale (GLS) improvement and return to baseline value using the Global Aesthetic Improvement Scale |
| 2024-02-28 | Galderma R&D | Results AAD 2024: scientific presentations supported by Galderma galderma.com ↗
Upward brow position change after treatment with abobotulinumtoxinA in the glabellar lines |
| 2024-01-19 | Ipsen | Results TOXINS 2024: Results from Ipsen’s AboLiSh study demonstrate the significant clinical benefit of using injection guidance techniques when treating spasticity with abobotulinumtoxinA ipsen.com ↗
Patients who received abobotulinumtoxinA (AboBoNT) injections with the support of injection guidance were nearly 3 times (2.7) more likely overall to achieve their rehabilitation goals. |
| 2024-01-17 | Galderma R&D | Results TOXINS 2024: Galderma’s phase III RelabotulinumtoxinA results demonstrate positive efficacy and long duration of effect when treating frown lines and crow’s feet simultaneously galderma.com ↗
Galderma announced today positive topline results from the phase III READY-3 clinical trial investigating the use of RelabotulinumtoxinA for the treatment of glabellar lines (frown lines) and lateral canthal lines (crow’s feet), either alone (single-area) or simultaneously. |
| 2023-11-30 | Galderma R&D | Results Results from Galderma’s phase IIIb trials demonstrate rapid and long-lasting effect of RelabotulinumtoxinA on crow’s feet and frown lines galderma.com ↗
Galderma announced today topline results from two phase IIIb trials investigating RelabotulinumtoxinA for the treatment of glabellar lines (GL – frown lines) and lateral canthal lines (LCL – crow’s feet). |
| 2023-11-06 | Evolus, Inc. | Results “Extra-Strength” 40U Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting evolus.com ↗
Final data were presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting on November 3, 2023, in Chicago, and demonstrated 26 weeks, or 6 months of duration with the extra-strength dose of 40U across multiple measurements. |
| 2023-10-24 | AbbVie | Results Allergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar Lines abbvie.com ↗
today announced positive topline results from two pivotal Phase 3 clinical studies evaluating trenibotulinumtoxinE (BoNT/E) for the treatment of moderate to severe glabellar lines (M21-500 and M21-508). |
| 2023-10-03 | Ipsen | Regulatory Ipsen updates on QM-1114 regulatory process ipsen.com ↗
Galderma has confirmed receipt from the FDA of a Complete Response Letter related to its Biologics License Application for liquid botulinum toxin type A (QM-1114) |
| 2023-09-18 | AbbVie | Results Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of OnabotulinumtoxinA (BOTOX® Cosmetic) for the Treatment of Platysma Prominence abbvie.com ↗
All primary and secondary endpoints were met for second Phase 3 study (M21-310) and results were consistent with findings from first Phase 3 study (M21-309). |
| 2023-06-12 | Merz Aesthetics Inc. | Results MERZ AESTHETICS ANNOUNCES POSITIVE PHASE 3 DATA DEMONSTRATING EFFICACY AND SAFETY OF XEOMIN® (incobotulinumtoxinA) IN TREATING UPPER FACIAL LINES merzaesthetics.com ↗
Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced today topline results from two pivotal phase 3 clinical studies demonstrating the efficacy and safety of Xeomin® (incobotulinumtoxinA) in the simultaneous treatment of upper facial lines (horizontal forehead lines, glabellar frown lines, and lateral canthal lines). |
| 2023-03-30 | Galderma R&D | Results AMWC 2023: Data from Sculptra® Cheek Wrinkle and Alluzience® Star Studies reinforce strength of Galderma’s broad aesthetic portfolio galderma.com ↗ |
| 2023-01-20 | Galderma R&D | Results IMCAS 2023: Galderma to share latest data demonstrating high aesthetic improvement and patient satisfaction across its innovative portfolio galderma.com ↗
This study shows high patient satisfaction and investigator preference for Alluzience over powder solutions and long duration of effect at six months |
| 2022-11-07 | AbbVie | Results AbbVie Announces Late-Breaking Results from Phase 2 Exploratory NOVA Trial of Novel Investigational Neurotoxin AGN-151607 for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery Patients abbvie.com ↗
AbbVie (NYSE: ABBV) today announced new results from its exploratory NOVA phase 2 dose-ranging study evaluating the efficacy and safety of AGN-151607, a novel investigational neurotoxin for the prevention of postoperative atrial fibrillation (POAF) in cardiac surgery patients. |
| 2022-10-07 | Galderma R&D | Results New data from Galderma's aesthetics portfolio to be presented at 2022 ASDS Annual Meeting galderma.com ↗
Results showed rapid onset of action, with 39% patients seeing results on Day 1 for frown lines and 34% on Day 1 for crow's feet and demonstrated long duration of action through six months |
| 2022-08-24 | Evolus, Inc. | Results Newly Published Post Hoc Analysis Evaluates Efficacy of Jeuveau® in Adult Males Compared to BOTOX® evolus.com ↗
Results demonstrated percentages of male responders treated with Jeuveau ® achieved approximately 10% higher results across all visits |
| 2022-06-10 | Galderma R&D | Results Galderma announces positive results in two phase III studies for a novel liquid formulation botulinumtoxinA (RelabotulinumtoxinA) for the treatment of glabellar lines (frown) and lateral canthal lines (crow’s feet) galderma.com ↗
Both studies met their primary endpoints with significantly higher response than placebo after one month for both frown lines and crow’s feet |
| 2022-05-31 | Galderma R&D | Results Galderma to present extensive new clinical data across its portfolio of neuromodulators, fillers and biostimulators at the IMCAS World Congress 2022 galderma.com ↗
Strong clinical data supporting Alluzience® (abobotulinumtoxinA, ABO), the first liquid, ready-to-use neuromodulator as an effective and well-tolerated treatment for glabellar (frown) lines, with a rapid onset and long duration of action of up to six months |
| 2021-11-19 | Merz Aesthetics Inc. | Results MERZ AESTHETICS TO PRESENT DATA FROM MEDICAL AESTHETICS PORTFOLIO AT THE AMERICAN SOCIETY OF DERMATOLOGIC SURGERY 2021 ANNUAL MEETING merzaesthetics.com ↗
Late Breaking: IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines: Final Study Results |
| 2021-08-31 | Merz Pharmaceuticals GmbH | Regulatory XEOMIN® (incobotulinumtoxinA) Receives European Approval for the Treatment of Chronic Sialorrhea in Children merz.com ↗ |
| 2021-08-31 | Merz Therapeutics GmbH | Regulatory XEOMIN® (incobotulinumtoxinA) receives european approval for the treatment of chronic sialorrhea in children merztherapeutics.com ↗ |
| 2021-06-23 | Teijin America, Inc. | Regulatory Teijin Receives Additional Approval in Japan for Merz’s Xeomin® Botulinum Toxin Type A[Teijin Pharma] teijin.com ↗
Teijin Pharma has been granted additional approval by Japan’s Ministry of Health, Labor and Welfare (MHLW) to market Xeomin® (incobotulinumtoxinA) for intramuscular injection in 50, 100 or 200 units for the treatment of lower limb spasticity. |
| 2021-06-23 | Merz Pharmaceuticals GmbH | Regulatory Teijin Receives Additional Approval in Japan for Merz’s Xeomin® Botulinum Toxin Type A merz.com ↗
Teijin Pharma has been granted additional approval by Japan’s Ministry of Health, Labor and Welfare (MHLW) to market Xeomin ® (incobotulinumtoxinA) for intramuscular injection in 50, 100 or 200 units for the treatment of lower limb spasticity. |
| 2021-06-23 | Merz Therapeutics GmbH | Regulatory Teijin receives additional approval in japan for Merz’s XEOMIN® Botulinum Toxin Type A merztherapeutics.com ↗
This label extension in Japan is another outstanding example for the benefits XEOMIN ® offers to many post-stroke spasticity patients. |
| 2021-04-29 | Merz Aesthetics Inc. | Results MERZ AESTHETICS TO PRESENT DATA FROM MEDICAL AESTHETICS PORTFOLIO AT “THE AESTHETIC MEETING 2021” IN MIAMI merzaesthetics.com ↗
IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines |
| 2020-11-18 | Galderma R&D | Regulatory Galderma launches Dysport® in China for treatment of glabellar lines galderma.com ↗
Dysport® (abobotulinumtoxinA) has received approval from the National Medical Products Administration of China (NMPA), making it the first new muscle relaxant approved for treatment of glabellar lines in China for eight years. |
| 2020-11-17 | Galderma R&D | Results Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA) galderma.com ↗
Results showed that the study met its primary endpoint, with significantly more subjects treated with Dysport® at all four doses achieving a composite two grade improvement responder rate than those treated with placebo at one month. |
| 2020-10-09 | Galderma R&D | Results Galderma To Present Five Abstracts in Support of Novel Aesthetics Solutions and Pipeline at ASDS 2020 Annual Meeting galderma.com ↗
Subjects are highly satisfied with two treatments of abobotulinumtoxinA a year: results from multi-center, year-long, longitudinal study |
| 2020-10-09 | Merz Aesthetics Inc. | Results MERZ AESTHETICS TO PRESENT DATA FROM MEDICAL AESTHETICS PORTFOLIO AT THE AMERICAN SOCIETY OF DERMATOLOGIC SURGERY 2020 ANNUAL MEETING merzaesthetics.com ↗
We’re excited to virtually participate at the ASDS meeting and share several data presentations from our leading treatment portfolio, which include findings on Xeomin’s safety and prolonged duration of effect in a dose-ranging study |
| 2020-10-08 | Medy-Tox | Regulatory 메디톡스, ‘메디톡신’ 국내 최초 우크라이나 시판허가 획득…글로벌 시장 선점 속도 medytox.com ↗
메디톡스, ‘메디톡신’ 국내 최초 우크라이나 시판허가 획득…글로벌 시장 선점 속도 |
| 2020-08-27 | UroGen Pharma Ltd. | Results UroGen Pharma Announces Update on the Phase 2 Trial of an RTGel™ Hydrogel Formulation in Combination with BOTOX® (onabotulinumtoxinA) Intravesical Instillation for Overactive Bladder and Urinary Incontinence urogen.com ↗
Data suggests that this result may have been due to BOTOX not effectively permeating the urothelium. |
| 2020-07-09 | AbbVie | Regulatory FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label for the Treatment of Pediatric Patients with Spasticity abbvie.com ↗ |
| 2020-07-01 | Merz Therapeutics GmbH | Regulatory Teijin receives marketing approval for Merz’s XEOMIN® Botulinum Toxin Type A in japan merztherapeutics.com ↗
Teijin Pharma has been granted approval by Japan’s Ministry of Health, Labor and Welfare (MHLW) to market XEOMIN ® (incobotulinumtoxinA) for intramuscular injection in 50, 100 or 200 units for the treatment of upper limb spasticity. |
| 2020-06-29 | Teijin America, Inc. | Regulatory Teijin Receives Marketing Approval for Merz’s Xeomin® Botulinum Toxin Type A in Japan[Teijin Pharma] teijin.com ↗
Teijin Pharma has been granted approval by Japan’s Ministry of Health, Labor and Welfare (MHLW) to market Xeomin® (incobotulinumtoxinA) for intramuscular injection in 50, 100 or 200 units for the treatment of upper limb spasticity. |
| 2020-06-29 | Merz Pharmaceuticals GmbH | Regulatory Teijin Receives Marketing Approval for Merz’s Xeomin® merz.com ↗
Teijin Pharma has been granted approval by Japan’s Ministry of Health, Labor and Welfare (MHLW) to market Xeomin ® (incobotulinumtoxinA) for intramuscular injection in 50, 100 or 200 units for the treatment of upper limb spasticity. |
| 2020-05-23 | Ipsen | Results New surveys show over 80% of patients with spasticity and cervical dystonia treated with botulinum toxin-A experience debilitating symptom recurrence ipsen.com ↗
The results show that over 80% of respondents experienced debilitating symptom recurrence, and revealed that a lack of long-lasting symptom control between injections has a profound impact on the personal and professional lives of patients. |
| 2020-01-06 | Ipsen | Regulatory Dysport® (clostridium botulinum type A toxin-haemagglutinin complex) now approved in the UK for symptomatic treatment of upper limb spasticity in children with cerebral palsy ipsen.com ↗
Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a licence update for Dysport® for the symptomatic treatment of focal spasticity of upper limbs in pediatric cerebral palsy patients, two years of age and older. |
| 2019-10-24 | Galderma R&D | Results Galderma Demonstrates Robust Aesthetic Innovation Pipeline with Initiation of Seven New Clinical Studies galderma.com ↗
AbobotulinumtoxinA efficacy lasts up to 5 months in the treatment of glabella |
| 2019-10-09 | Galderma R&D | Results Galderma Announces Positive Phase 2 Results for its Proprietary Liquid Formulation of an Investigational Botulinum Toxin and Approval of New State-of-the-Art Manufacturing Facility galderma.com ↗
The multicenter, randomized, double-blind, placebo-controlled study successfully demonstrated the safety and efficacy of Galderma’s liquid formulation of botulinum toxin type A for the treatment of glabellar lines (frown lines). |
| 2019-09-23 | Ipsen | Results Ipsen announces positive results from Phase IIIb/IV ENGAGE study of the combination of Dysport® (abobotulinumtoxinA) with Guided Self-rehabilitation Contracts in adult patients with upper and lower limb spastic hemiparesis ipsen.com ↗
This study provides insight into treatment strategies that can improve the outcomes of patients living with spastic paresis, specifically the role of Guided Self-rehabilitation Contracts combined with Dysport for the improvement of voluntary movement, an area of limited data availability. |
| 2019-07-11 | Daewoong Pharmaceutical Co. LTD. | Results Daewoong Pharmaceutical’s ‘Nabota’ enters IMCAS Asia 2019… Announces its excellence to medical practitioners from all over the world. daewoong.co.kr ↗
In this respect, Daewoong Pharmaceutical’s Botulinum Toxin has proven its efficacies and safety through U.S. FDA approval and equivalence compared to Botox in all aspects, including improvement of frown lines and safety, through the global clinical studies. |
| 2019-05-29 | Merz Pharmaceuticals GmbH | Regulatory Xeomin® (incobotulinumtoxinA) Receives European Approval for Treatment of Chronic Sialorrhea in Adults merz.com ↗
Merz, a global leader in neurotoxin therapy, announced today the European approval of Xeomin ® (incobotulinumtoxinA) for the symptomatic treatment of chronic sialorrhea (drooling) due to neurological disorders in adult patients. |
| 2019-05-29 | Merz Therapeutics GmbH | Regulatory XEOMIN® (incobotulinumtoxinA) receives european approval for treatment of chronic sialorrhea in adults merztherapeutics.com ↗
Merz, a global leader in neurotoxin therapy, announced today the European approval of XEOMIN ® (incobotulinumtoxinA) for the symptomatic treatment of chronic sialorrhea (drooling) due to neurological disorders in adult patients. |
| 2019-05-08 | Daewoong Pharmaceutical Co. LTD. | Results Daewoong Pharmaceutical hosted a symposium titled ‘NABOTA Sparkling Night’ in Thailand daewoong.co.kr ↗
Nabota has proven non-inferiority in terms of improvement of frown lines and safety through a comparative clinical study with Allergan’s Botox, |
| 2019-04-12 | Daewoong Pharmaceutical Co. LTD. | Results The clinical findings of Botulinum Toxin manufactured by Daewoong have been published on international journal regarding the comparison with Botox daewoong.co.kr ↗
As a result, 87.2% of the JEUVEAU group and 82.8% of the Botox group showed improvement of Glabellar Line to GLS 0 or 1. |
| 2019-04-08 | Evolus, Inc. | Results Evolus Announces Publication of Largest Aesthetic Head-to-Head Pivotal Trial Comparing Jeuveau™ and BOTOX® in Aesthetic Surgery Journal evolus.com ↗
Primary Endpoint of Non-Inferiority Achieved with Responder Rates* of 87.2% for Jeuveau™, 82.8% for BOTOX ® and 4.2% for Placebo at Day 30 |
| 2019-01-17 | Ipsen | Results Ipsen presents the results of the first in-human study of a recombinant fast-acting neurotoxin (rBoNT-E) at TOXINS 2019 ipsen.com ↗
The study also reported that it has a faster onset of action and a shorter duration of effect, as well as a quick time to peak activity, in comparison with established BoNT-A products. |
| 2018-11-28 | Daewoong Pharmaceutical Co. LTD. | Results Daewoong Pharmaceutical successfully held ‘NABOTA SEOUL 2018’ daewoong.co.kr ↗
Nabota(DWP-450) proved its non-inferiority compared to Botox in various clinical studies conducted in Korea, US, Canada and Europe. |
| 2018-09-14 | AbbVie | Results Allergan Highlights Key Growth Drivers for Medical Aesthetics abbvie.com ↗
The study met its primary endpoint confirming long-held belief that higher doses of botulinum toxin produce greater duration of treatment effect. |
| 2018-09-14 | AbbVie | Results Allergan Announces Results of Higher Dose BOTOX® Cosmetic (onabotulinumtoxinA) for the Treatment of Moderate to Severe Glabellar Lines abbvie.com ↗
Allergan plc (NYSE: AGN) today announced clinical study results of higher doses of BOTOX® Cosmetic compared to BOTOX® Cosmetic 20 unit dose at week 24 in patients with moderate to severe glabellar lines. |
| 2018-08-30 | Medy-Tox | Regulatory 메디톡스, ‘메디톡신’ 대만 시판 허가 신청 완료…“화교 경제권 공략” medytox.com ↗
바이오제약 기업 메디톡스 ( 대표 정현호 ) 는 지난 28 일 대만 식품의약국 (TFDA) 에 보툴리눔 톡신 제제 ‘메디톡신 ( 수출명 : 뉴로녹스 ) ’의 시판 허가 (BLA) 신청을 완료 했다고 29 일 밝혔다 . |
| 2018-07-04 | Ipsen | Results Ipsen announces new clinical data to be presented at ISPRM 2018 demonstrating commitment to neurotoxin research ipsen.com ↗
This study demonstrated that pain reduction is an important and achievable primary treatment goal in some patients suffering with spasticity. |
| 2018-04-05 | Evolus, Inc. | Results Evolus Phase III European - Canadian Head-to-Head Trial of prabotulinumtoxinA Compared to Botox® Meets Primary Endpoint evolus.com ↗ |
| 2016-03-17 | Merz Pharmaceuticals GmbH | Regulatory Merz Announces European Approval of Bocouture for the Treatment of Upper Facial Lines merz.com ↗
Merz Pharma Group today announced that Bocouture ® has been approved by European regulatory authorities for the treatment of upper facial lines, including horizontal frown lines, lateral periorbital lines and glabellar frown lines. |
| 2015-12-11 | Merz Pharmaceuticals GmbH | Regulatory Alternative Test Method for Botulinum Neurotoxin Now Approved in Europe merz.com ↗
The BfArM and all the other drug regulatory authorities in the European Union have approved the alternative method for testing the Merz products containing botulinum neurotoxin type A throughout the EU. |
| 2015-06-10 | Merz Pharmaceuticals GmbH | Regulatory Landmark Change for Botulinum Neurotoxin: Alternative Test Method Approved in the U.S. merz.com ↗
The FDA, the U.S. drug regulatory authority, has approved an in vitro assay developed by Merz for establishing the potency and stability of its botulinum neurotoxin. |
| 2009-12-10 | XOMA (US) LLC | Results XOMA Presents Advantages of Its Multiple Antibody Formulation Technologies at Antibody Engineering Conference xoma.com ↗
XOMA 3AB is comprised of three human antibodies that bind to unique epitopes on the botulinum A toxin, which in composite provide unprecedented potency against the toxin. |
| 2009-09-21 | Galderma R&D | Regulatory Azzalure ® approved in Spain for aesthetic use in the treatment of glabellar lines galderma.com ↗
Azzalure ® approved in Spain for aesthetic use in the treatment of glabellar lines |
| 2009-06-26 | Galderma R&D | Regulatory Azzalure ® approved in Germany for aesthetic use in the treatment of glabellar lines galderma.com ↗
Azzalure ® approved in Germany for aesthetic use in the treatment of glabellar lines |
| 2009-03-30 | Galderma R&D | Regulatory Azzalure ® is approved in France for aesthetic use in the treatment of frown lines galderma.com ↗
The marketing approval is for the temporary improvement in the appearance of moderate to severe glabellar lines seen at the frown (vertical lines between the eyebrows), in adult men and women aged 65 years and under, when the severity of these lines has an important psychological impact on the patient. |
| 2009-03-12 | Galderma R&D | Regulatory Azzalure ® approved in the UK for aesthetic use in the treatment of glabellar lines galderma.com ↗
Azzalure ® approved in the UK for aesthetic use in the treatment of glabellar lines |
| 2009-02-02 | Galderma R&D | Regulatory The Health Authorities of 15 European countries give a collective green light to Azzalure ® galderma.com ↗
Ipsen (Euronext: IPN), an international innovation-driven specialty pharmaceutical Group, and Galderma, the leading pharmaceutical company in dermatology, today announced that Azzalure ®, a muscle relaxant specifically developed for aesthetic use, has received the collective green light from 15 European countries’ Health Authorities for the granting of national marketing authorizations. |
All press releases naming this drug 151 releases
| Date | Issuer | Release |
|---|---|---|
| Show all 151 releases opens the full record — a long page | ||
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 71 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Botulinum Toxin | “The aim of this prospective non-randomized study was to assess the efficacy and safety of endomyocardial botulinum toxin injection in left ventricle for preventing episodes of VT Storm.” NCT02003027 ↗62“While Botulinum toxin(BoNT) injections are widely used for focal spasticity, surgical interventions remain underutilized despite promising long-term outcomes.” NCT06733025 ↗ “Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster).” NCT02008448 ↗ “This project aims to explore the therapeutic effect of Botulinum toxin (Botox) injection to the masticatory muscles in the above-mentioned patients.” NCT06734598 ↗ “Local injection of Botulinum toxin (BTx) has become a mainstay of the treatment of focal spasticity, particularly in post-stroke patients.” NCT01829763 ↗ “The investigators assume that intramuscular injection of botulinum toxin is effective in the treatment of tendinopathy rotator cuff.” NCT02867787 ↗ “Botulinum toxin produces partial chemical denervation of the muscle resulting in localized reduction in muscle activity” NCT04030767 ↗ “Botulinum toxin treatment results in a pharmacologic recession of the injected extraocular muscle” NCT07180394 ↗ “Focal injections of botulinum toxin (BoNT) are the current best therapy.” NCT02015039 ↗ “Botulinum Toxin diluted in Sodium Bicarbonate” NCT04579419 ↗ “Botulinum toxin” NCT01631604 ↗ |
| Known as | BoNT | “The purpose of this study is to evaluate if it is possible to use intravaginal high-density surface electromyography to guide Botulinum neurotoxin (BoNT) injection to treat...” NCT05062902 ↗3“While Botulinum toxin(BoNT) injections are widely used for focal spasticity, surgical interventions remain underutilized despite promising long-term outcomes.” NCT06733025 ↗ “Focal injections of botulinum toxin (BoNT) are the current best therapy.” NCT02015039 ↗ “Botulinum neurotoxin (BoNT) is the first-line treatment of ICD” PMID 31478151 ↗ Sep 2019 |
| Known as | BoNTA | “intradetrusor injection of botulinum neurotoxin type A (BoNTA)” NCT07025642 ↗ |
| Known as | Botox | “This project aims to explore the therapeutic effect of Botulinum toxin (Botox) injection to the masticatory muscles in the above-mentioned patients.” NCT06734598 ↗6“Botulinum toxin (BTX, brand name Botox®), produced naturally by the bacterium Clostridium botulinum and adapted for medical use” NCT03701919 ↗ “Urodynamic evaluation before and after Botulinum toxin (Botox) injection.” NCT07025642 ↗ “A single session of Botox (Botulinum toxin A) injection was performed.” NCT06583551 ↗ “one hundred units of type A botulinum toxin (Botox®, Allergan)” NCT01955174 ↗ “Botulinum Toxin commonly known as BOTOX®” NCT01422161 ↗ “Biological: Botulinum toxin(Botox)” NCT04523506 ↗ |
| Known as | Botulin toxin | “patients with spastic hemiparesis which will be treated with Botulin toxin at different dilutions.” NCT04630873 ↗ |
| Known as | Botulinum neurotoxin | “Botulinum neurotoxin (BoNT) is the first-line treatment of ICD” PMID 31478151 ↗ Sep 2019 |
| Known as | botulinum neurotoxin type A | “intradetrusor injection of botulinum neurotoxin type A (BoNTA)” NCT07025642 ↗ |
| Known as | Botulinum toxin A | “A single session of Botox (Botulinum toxin A) injection was performed.” NCT06583551 ↗1“Botulinum toxin A injection” NCT00701233 ↗ |
| Known as | Botulinum Toxin Type A | “Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease” NCT02472210 ↗ |
| Known as | BTX | “Local injection of Botulinum toxin (BTx) has become a mainstay of the treatment of focal spasticity, particularly in post-stroke patients.” NCT01829763 ↗3“Botulinum toxin (BTX, brand name Botox®), produced naturally by the bacterium Clostridium botulinum and adapted for medical use” NCT03701919 ↗ “Improvement of cervical/eyelid control following botulinum toxin (BTX) injections would translate into gait changes.” PMID 38386480 ↗ Dec 2023 “Botulinum neurotoxin (BTX)” NCT03302741 ↗ |
| Known as | BTX-A | “The study aimed to assess and compare the effectiveness of 4 different methods in the management bruxism: Botulinum toxin (BTX-A), dry needling (DN), pharmacological therapy...” NCT06583551 ↗2“OBJECTIVE: To determine the effects of botulinum neurotoxin type A (BTX-A) dilution and endplate-targeting in spastic elbow flexors.” PMID 19154823 ↗ Jan 2009 “botulinum toxin injection (BTX A)” NCT06411028 ↗ |
| Known as | Dysport | “A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient” NCT00927849 ↗1“Botulinum Toxin type-A (Dysport, Ipsen Ltd, Slough, Berkshire)” NCT00973999 ↗ |
| Known as | incobotulinumtoxin A | “All patients underwent conventional CABG. After the main stage of the surgery botulinum toxin (Xeomin, incobotulinumtoxin A, Merz Pharma GmbH \& Co KGaA, Germany; 50 U/1 mL at...” NCT01842529 ↗ |
| Known as | Intramuscular injection of Botulinum toxin A. (BoNT-A) | “Intramuscular injection of Botulinum toxin A. (BoNT-A)” NCT06583551 ↗ |
| Known as | Xeomin | “Patients with history of paroxysmal atrial fibrillation and indication for coronary artery bypass graft surgery were randomized to botulinum toxin (Xeomin, Merz, Germany; 50...” PMID 26486855 ↗ Oct 2015 |
| Action | Inhibit | “botulinium toxin, which inhibitis acetyl choline realese” NCT00767546 ↗ |
| Modality | Protein / enzyme biologic | “Biological: botulinum toxin injection” NCT01842529 ↗ |
| Route | Other | “after local injection with Botox” NCT00119886 ↗ |